Approximately 100,000 people in the U.S. will be diagnosed with melanoma this year, according to the American Cancer Society.

For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

The revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...